+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
GPTHEALTH

GPT Healthcare Share Price

₹143.94 +2.9 (2.06%)
25.17% Gain from 52W Low

05 Nov, 2026 3:31 PM (IST)

GPT Healthcare live price: ₹143.94. It opened at ₹144 vs previous close ₹141; intraday high/low: ₹145/₹141. The 50 & 200 DMA stand at ₹145.70/₹147.10.

GPT Healthcare Performance

  • Today's Low
  • ₹141
  • Today's High
  • ₹145
  • 52 Week Low
  • ₹115
  • 52 Week High
  • ₹175
  • Open Price₹144
  • Previous Close₹141
  • Volume101,592
  • 50 DMA₹145.70
  • 100 DMA₹147.70
  • 200 DMA₹147.10

GPT Healthcare Chart

Investment Returns

  • Over 1 Month -4.97%
  • Over 3 Month -11.24%
  • Over 6 Month + 1.76%
  • Over 1 Year -3.14%

Smart Investing Starts Here Start SIP with GPT Healthcare for Steady Growth!

Invest Now

GPT Healthcare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25
  • PEG Ratio
  • -32.3
  • Market Cap Cr
  • 1,181
  • P/B Ratio
  • 4.2
  • Average True Range
  • 5.3
  • EPS
  • 5.8
  • Dividend Yield
  • 1.7
  • MACD Signal
  • -4
  • RSI
  • 49.53
  • MFI
  • 37.57

Latest Stock News Updates

GPT Healthcare Ltd - 544131 - Board Meeting Outcome for Outcome Of Board Meeting Held On November 5, 2026

Please find enclosed herewith the Outcome of the Board Meeting held on November 5, 2026.

GPT Healthcare Ltd - 544131 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Please find enclosed intimation letter for the earnings call scheduled to be held on November 6, 2026 to discuss the performance of the Company for Q2 & H1 FY 2027.

GPT Healthcare Ltd - 544131 - Board Meeting Intimation for Considering And Approving Interalia The Unaudited Financial Results Along With Limited Review Report For The 2Nd Quarter And Half Year Ended On September 30, 2026 And To Declare Interim Dividend For The FY 2026-27.

GPT Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve 1. the Unaudited Financial Results along with Limited Review Report of the Statutory Auditors thereon of the Company for the 2nd quarter and half year ended on September 30, 2026 2.the declaration of interim dividend for the FY 2026-27, if any, on the equity share capital of the company.

GPT Healthcare Financials

GPT Healthcare Technicals

EMA & SMA

Current Price
₹143.94
+ 2.9 (2.06%)
pointer
  • Bearish Moving Average 6
  • Bullish Moving Average 10
  • 20 Day
  • ₹139.30
  • 50 Day
  • ₹145.70
  • 100 Day
  • ₹147.70
  • 200 Day
  • ₹147.10

Resistance and Support

143.18 Pivot Speed
  • R3 151.30
  • R2 147.30
  • R1 144.20
  • S1 137.00
  • S2 132.90
  • S3 129.80

GPT Healthcare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-11-05 Quarterly Results & Interim Dividend
2026-08-03 Quarterly Results
2026-05-18 Audited Results & Final Dividend
2026-02-02 Quarterly Results
2025-11-08 Quarterly Results & Interim Dividend
Date Purpose Remarks
2026-07-30 FINAL Rs.1.50 per share(15%)Final Dividend
2025-11-14 INTERIM Rs.1.00 per share(10%)Interim Dividend
2025-07-29 FINAL Rs.1.50 per share(15%)Final Dividend
2024-11-28 INTERIM Rs.1.00 per share(10%)First Interim Dividend
2024-04-02 INTERIM Rs.1.00 per share(10%)Interim Dividend
View GPT Healthcare Dividend History Arrow

GPT Healthcare Shareholding Pattern

65.57%
24.32%
4.61%
3.01%
2.49%

GPT Healthcare FAQs

GPT Healthcare share price is ₹143 As on 05 November, 2026 | 16:57

The Market Cap of GPT Healthcare is ₹1181.1 Cr As on 05 November, 2026 | 16:57

The P/E ratio of GPT Healthcare is 25 As on 05 November, 2026 | 16:57

The PB ratio of GPT Healthcare is 4.2 As on 05 November, 2026 | 16:57

The 52 week High & Low of GPT Healthcare is ₹175/₹115 respectively As on 05 November, 2026 | 16:57

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23